Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Abstract Resistance to aromatase inhibitor (AI) treatment and combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) are crucial clinical challenges in treating estrogen receptor-positive (ER+) breast cancer. Understanding the resistance mechanisms and identifying reliable predictive biomark...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Abeer J. Al-Qasem, Carla L. Alves, Sidse Ehmsen, Martina Tuttolomondo, Mikkel G. Terp, Lene E. Johansen, Henriette Vever, Luna V. A. Hoeg, Daniel Elias, Martin Bak, Henrik J. Ditzel
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2022-09-01
Edice:	npj Precision Oncology
On-line přístup:	https://doi.org/10.1038/s41698-022-00311-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!